Las Vegas: Are Frontotemporal Dementia Models Fit for Pharma?
Some 65 representatives from academia, industry, advocacy groups, and government agencies tried to illuminate a path toward treatments for frontotemporal dementia...
6400 RESULTS
Sort By:
Some 65 representatives from academia, industry, advocacy groups, and government agencies tried to illuminate a path toward treatments for frontotemporal dementia...
Scientists are beginning to get a handle on what happens in multiple concussions, but little research exists on how brains respond to the pressure waves from explosions...
Researchers report that memantine is no better than placebo for people with mild AD, and only marginally effective in moderate cases...
Athletes who suffer repeated concussions in high-impact sports such as boxing, football, and hockey are at risk for long-term brain damage...
Designed by world-class architect Frank Gehry, the Cleveland Clinic Lou Ruvo Center for Brain Health opened its doors in Las Vegas in 2009...
Traumatic brain injury (TBI) has become a hot topic...
The wars of the last decade have highlighted the effects of traumatic brain injuries (TBIs) and post-traumatic stress disorder (PTSD)...
New diagnostic criteria for Alzheimer’s disease and for its preclinical manifestations formally appeared online today...
Inflammation is common in neurodegenerative diseases, but scientists are not yet sure how it relates to pathology...
Honolulu: So Far, So Good in Stem Cell Safety Study for ALS American Academy of Neurology: 2011 Annual Meeting
Injecting neural stem cells into the lumbar spinal cord is a safe procedure for people with amyotrophic lateral sclerosis...
As scientists continue to pursue disease-modifying treatments for Alzheimer’s disease, various forms of oligomers have become the target du jour...
House and Senate budget negotiators not only spared the country a government shutdown, they also largely spared the NIH budget from drastic reductions...
Better AD treatments are urgently needed, and a decade of setbacks in the clinic has left researchers searching for new ideas...
Dimebon, aka latrepirdine, failed to show efficacy in a Phase 3 clinical trial of people with Huntington’s disease...